top of page
Our activities
We are committed to a spear heading a channel of innovation through collaboration and partnerships. Stay connected with us to see our most recent activities from tri-lateral forum and symposiums to R&D funding activities
News Release
Day Two: 2025 Life Science, Digital & Health Open Innovation Forum
Day Two: 2025 Life Science, Digital & Health Open Innovation Forum Life Science, Digital & Health Open Innovation Forum in London 2025
We held ‘UK, Korea, and Japan - Life Science, Digital & Healthcare Open Innovation Forum’ on March 4th in London.
The Forum focused on bringing together leading Korean and Japanese LPs, CVCs, Global GPs, and drug discovery enterprises to foster cross-border collaboration, drive investment, and accelerate the growth of life science opportunities in the UK on a global scale.
As Europe’s largest venture capital market, the UK is a premier hub for life science investment, R&D, and open innovation, supported by world-class academic institutions and a thriving spin-out, and investment landscape.
Aligned with the UK Government’s vision to advance the life science-digital-healthcare investment environment, the Forum will unite top-tier international and local investors, innovators, and industry leaders in dedication to share valuable insights, identify emerging trends, and establish strategic collaborations.
Ultimately, we hoped it had served as a platform for developing a strategic investment ecosystem that will shape the future of bio-healthcare innovation.
We held ‘UK, Korea, and Japan - Life Science, Digital & Healthcare Open Innovation Forum’ on March 4th in London.
The Forum focused on bringing together leading Korean and Japanese LPs, CVCs, Global GPs, and drug discovery enterprises to foster cross-border collaboration, drive investment, and accelerate the growth of life science opportunities in the UK on a global scale.
As Europe’s largest venture capital market, the UK is a premier hub for life science investment, R&D, and open innovation, supported by world-class academic institutions and a thriving spin-out, and investment landscape.
Aligned with the UK Government’s vision to advance the life science-digital-healthcare investment environment, the Forum will unite top-tier international and local investors, innovators, and industry leaders in dedication to share valuable insights, identify emerging trends, and establish strategic collaborations.
Ultimately, we hoped it had served as a platform for developing a strategic investment ecosystem that will shape the future of bio-healthcare innovation.
[ChosunBiz] Exclusive Interview with Sir. Professor David Klernerman
Professor Sir David Klenerman has been featured in an exclusive interview with one of Korea's largest news agency Chosun Biz. The interview was held during our March "2025 Life Science, Digital and Health Open Innovation Forum".
About Professor Sir David Klenerman
Professor Sir David Klenerman is the Royal Society GSK Professor of Molecular Medicine at the Yusuf Hamied Department of Chemistry, University of Cambridge.
His recognition includes being knighted by the Queen in 2018, for development of high speed DNA sequencing, and being awarded the Royal Society’s Royal Medal in 2018. He was awarded the 2020 Millennium Technology Prize jointly with Shankar Balasubramanian and the 2022 Breakthrough Prize for Life Sciences and 2024 Gairdner Prize for Life Sciences jointly with Shankar Balasubramanian and Pascal Mayer for next generation DNA sequencing. (Courtesy of UK Dementia Research Institute)
Follow the link below for access to the article:
About Professor Sir David Klenerman
Professor Sir David Klenerman is the Royal Society GSK Professor of Molecular Medicine at the Yusuf Hamied Department of Chemistry, University of Cambridge.
His recognition includes being knighted by the Queen in 2018, for development of high speed DNA sequencing, and being awarded the Royal Society’s Royal Medal in 2018. He was awarded the 2020 Millennium Technology Prize jointly with Shankar Balasubramanian and the 2022 Breakthrough Prize for Life Sciences and 2024 Gairdner Prize for Life Sciences jointly with Shankar Balasubramanian and Pascal Mayer for next generation DNA sequencing. (Courtesy of UK Dementia Research Institute)
Follow the link below for access to the article:
Day One: 2025 Life Science, Digital & Health Open Innovation Forum
On March 3rd, we held day one of our forum at the Royal Society in London, with the aim of uniting the collective expertise of ‘UK, Korea and Japan - Life Science, Digital Technology & Healthcare’ to tackle critical health and disease-related challenges.
The Forum was co-hosted by Medical Research Council and King's College London.
On the first day, we had a turnout of over 80 guests where we successfully fostered a multidisciplinary ‘Open Innovation’ platform that bridged academia, industry and government organisations from UK , Korea and Japan.
We were excited to receive participation and presentation from the Department for Science, Innovation and Technology, the Department for Business and Trade, Department of Health and Social Care, Medical Research Council, King's College London, Drug Discovery Institute Oxford, Rosalind Franklin Institute, Harwell Science and Innovation Campus from the UK🇬🇧, and JETRO - Japan External Trade Organization London, Japan Agency for Medical Research and Development (AMED) from Japan.
The programme was organised by Prof. Chas Bountra (University of Oxford), Prof. Kei Cho (King’s College London), Mr. Jonathan Crook (Department for Business & Trade), Mr. Sebastian Johnson (Advanced Research Clusters Harwell) and Dr. Mark Palmer (Medical Research
Council). Prof. Kei Cho opened the Forum at the Royal Society, Wolfson Library, London.
The Forum served as the cornerstone for the development of ‘Strategic Partnerships’ and improved OPEN INNOVATION ECOSYSTEM and “Golden-Triangle” R&D Opportunities (UK-Japan-Korea). United Kingdom, Japan and South Korean government bodies, associated agents and industries exchanged the idea of trilateral collaboration.
The Forum discussed how can Life Science-Digital/Artificial Intelligence (AI) & Technology be
used synergistically to provide a better understanding of biological mechanisms associated with health/disease and foster open-innovation platforms, providing better solutions to improve the quality of life.
The Forum was co-hosted by Medical Research Council and King's College London.
On the first day, we had a turnout of over 80 guests where we successfully fostered a multidisciplinary ‘Open Innovation’ platform that bridged academia, industry and government organisations from UK , Korea and Japan.
We were excited to receive participation and presentation from the Department for Science, Innovation and Technology, the Department for Business and Trade, Department of Health and Social Care, Medical Research Council, King's College London, Drug Discovery Institute Oxford, Rosalind Franklin Institute, Harwell Science and Innovation Campus from the UK🇬🇧, and JETRO - Japan External Trade Organization London, Japan Agency for Medical Research and Development (AMED) from Japan.
The programme was organised by Prof. Chas Bountra (University of Oxford), Prof. Kei Cho (King’s College London), Mr. Jonathan Crook (Department for Business & Trade), Mr. Sebastian Johnson (Advanced Research Clusters Harwell) and Dr. Mark Palmer (Medical Research
Council). Prof. Kei Cho opened the Forum at the Royal Society, Wolfson Library, London.
The Forum served as the cornerstone for the development of ‘Strategic Partnerships’ and improved OPEN INNOVATION ECOSYSTEM and “Golden-Triangle” R&D Opportunities (UK-Japan-Korea). United Kingdom, Japan and South Korean government bodies, associated agents and industries exchanged the idea of trilateral collaboration.
The Forum discussed how can Life Science-Digital/Artificial Intelligence (AI) & Technology be
used synergistically to provide a better understanding of biological mechanisms associated with health/disease and foster open-innovation platforms, providing better solutions to improve the quality of life.
[Alzheimer's Research UK] Award Sponsor
On the 16th Sep 2024, it was a great honour to sponsor the awards for two prize winners at Alzheimer’s Research UK’s Science Day 2024 @RoyalSociety
[SEOUL BIO HUB] Open Innovation with Daewon Pharmaceutical
We are pleased to share the news that SD&K is leading the Open Innovation Programme, supported by Seoul Bio Hub, for two bio-startups specialising in DDS (Drug Delivery Systems), in collaboration with Daewon Pharmaceutical.
As part of our exciting journey, we held an opening ceremony with Seoul Metropolitan City and KIST.
As part of our exciting journey, we held an opening ceremony with Seoul Metropolitan City and KIST.
The 2nd UK-Korea Bio & Technology Forum
The Credit Finance Association of Korea
bottom of page